It is with great pleasure I announce, *Journal of Circulating Biomarkers* (*JCB*) is now indexed in PubMed Central (PubMed). I want to take this opportunity to thank the contributions from Editors in Chief, Shidong Jia, and Shu-Wing Ng for past contributions, as well as our Associate Editors and Editorial Board members for their enduring support.

Indexing in PubMed Central has been a major focus of the journal up to now, so we are delighted to have reached this milestone. Indexing will improve the visibility and discoverability of our content and is therefore be a great benefit to our authors, both past and future. Our next challenge will be to obtain indexing in the Web of Science and Science Citation Index Expanded database and so receive an Impact Factor. This ambitious task will require continued support from our Editorial Board, authors, and readers, so I thank you now in advance.

*JCB* will continue to maintain a high standard, to publish the best science-driven and implementation studies of any circulating biomarker, that will move the basic and clinical research field forward. In doing so, we update our editorial roles, by recruiting new Editors in Chief, Associate Editors, and Editorial Board members, to assist me in achieving our next milestone. For those who are interested, feel free to contact me directly.

*JCB* is positioned to broadly publish, but not exclusively, the fast growing interest in liquid biopsy across many disease indications, as well as the therapeutic aspect for immunotherapy and CAR-T cells, technology development of new methods for isolation, characterization and tracking, and the basic science research to provide a foundation for the former to be possible. Topics related to circulating biomarkers (found in any biofluid), not limited, but including extracellular vesicles (exosomes, microvesicles, ectosomes, apoptotic bodies, platelet dust, etc.) cell-free DNA, circulating tumor DNA, circulating tumor cells, platelets, free floating nucleic acids, and others, as it is related to health and disease. This will include studies that involve animal models that will provide insight to the function, detection, implementation of a method for human benefit, evaluating delivery methods for therapeutics, and so on.

I encourage our Associate Editors and Editorial members to submit manuscripts too. *JCB* will continue to accept original and review articles as well as perspectives, short research reports, protocols and methods, clinical trial reports, notes to the Editor, letters to the Editor, and conference/meeting dispatch reports. Manuscripts selected for publication should contain high-quality, reproducible data that advance the circulating biomarker field both at the basic and clinical aspects and contribute to a broader understanding of the underlying processes for each study.

As part of our continued growth and efforts to support the field, *JCB* will look to establish partnerships with scientific societies, and academic and industry leaders to advance the field and to allow free access to knowledge in the circulating biomarker space.

I want to conclude by sending my sincere gratitude to my fellow Editors in Chief, Editorial team, and our authors and readers for your continuous support, and I look forward to working with everyone as we move into the next phase of the journal.
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